Legend Biotech, uniQure, Myriad Genetics Schedule Q4 and Full Year 2025 Earnings Calls
Myriad Genetics, uniQure, and Legend Biotech have scheduled Q4 and full year 2025 earnings calls for Feb 23, Mar 2, and Mar 10, 2026, respectively. Details include webcast access, dial-in numbers, and company background.
Three biotech companies have scheduled conference calls to review their fourth-quarter and full-year 2025 financial results. Myriad Genetics, Inc. will host its earnings call on February 23, 2026, uniQure N.V. on March 2, 2026, and Legend Biotech Corporation on March 10, 2026.
Myriad Genetics will release its fourth quarter and full year 2025 financial results on February 23, 2026, after the market closes, and will host a conference call at 4:30 pm ET the same day. The live webcast will be accessible on the company's Investor Relations website. The company's president and CEO and its CFO will also present at several upcoming investor healthcare conferences. Myriad Genetics is focused on advancing health through genetic testing and precision medicine, aimed at improving patient care and reducing healthcare costs.
uniQure will announce its 2025 financial results on March 2, 2026, prior to market opening, followed by a conference call at 8:00 a.m. ET. Analysts can participate by dialing (646) 307-1963 or toll-free (800) 715-9871 with conference ID 4607289. The webcast will be available in the Events & Presentations section of the company's website. uniQure is a gene therapy company known for its gene therapy treatment for hemophilia B and is developing additional therapies for conditions including Huntington's disease, ALS, and Fabry disease.
Legend Biotech will host an investor conference call at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results. Senior management will provide an overview of quarterly and full-year financial performance. A replay of the webcast will be available approximately two hours after the conclusion of the call in the Investor Relations section of the Legend Biotech website. Legend Biotech, with over 2,900 employees, is the largest standalone cell therapy company. It develops and markets CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, with collaborator Johnson & Johnson.